Skip to main content
. 2019 Jun 24;18(2):33–46. doi: 10.12779/dnd.2019.18.2.33

Fig. 5. Decision platform suggested by the K-ARPI. (A) Prescreening of AD patients for clustering with genetic information and clinical characteristics, imaging, biomarkers, and analysis. (B) Reclassification of prescreened clusters according to the algorithm using standardized biomarkers. (C) Schematic summary of the decision platform of the K-ARPI.

Fig. 5

K-ARPI: Korean AD Research Platform Initiative based on Immune-inflammatory biomarkers, AD: Alzheimer's disease, PET: positron emission tomography, CSF: cerebrospinal fluid.